Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacologic therapy for HIV-associated lipodystrophy.

Sandra Benavides1, Milap C Nahata

  • 1College of Pharmacy, Ohio State University, Columbus, OH 43210, USA.

The Annals of Pharmacotherapy
|February 3, 2004
PubMed
Summary

No current drug effectively treats HIV-associated lipodystrophy. While some therapies like recombinant human growth hormone show promise for fat redistribution, they carry risks. Individualized treatment is crucial.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment Patterns and Barriers to Care Among U.S. Adults With Co-Occurring Substance Use Disorder and Mental Illness.

The American journal of psychiatry·2026
Same author

Efficacy and Safety of Combination Pharmacotherapies With Standard Diuretic Therapy in Acute Heart Failure: A Systematic Review and Meta-Analysis.

Cardiology in review·2026
Same author

Patterns of Dietary Supplement Use for Weight Loss Among U.S. Adults With Obesity: NHANES 2007-2020.

Journal of obesity·2026
Same author

Trends in Weight Loss Attempts and Strategies Among US Adolescents With Overweight or Obesity.

Obesity (Silver Spring, Md.)·2026
Same author

The global burden of mental and substance use disorders among adolescents and young adults.

Molecular psychiatry·2026
Same author

Patterns of psychotropic medication use, medication switching, augmentation, and non-persistence in adolescents and young adults with co-occurring psychiatric morbidities and opioid use disorder.

BMC psychiatry·2026

Area of Science:

  • Endocrinology
  • Infectious Diseases
  • Pharmacology

Background:

  • HIV-associated lipodystrophy is increasingly prevalent, characterized by fat redistribution and metabolic issues.
  • Key features include visceral adipose tissue (VAT) accumulation, dorsocervical fat (buffalo hump), and subcutaneous adipose tissue (SAT) depletion.
  • Metabolic abnormalities like dyslipidemia and insulin resistance are common comorbidities.

Purpose of the Study:

  • To assess the efficacy and safety of drug therapies for HIV-associated lipodystrophy, specifically focusing on fat redistribution.
  • To review treatments beneficial in other lipodystrophy forms and currently under investigation for HIV-associated cases.

Main Methods:

  • A comprehensive MEDLINE search was conducted from 1996 to February 2003.
  • Bibliographies of retrieved articles were reviewed for additional relevant studies.
  • Abstracts from major scientific meetings in 2002 and 2003 were also incorporated.

Main Results:

  • Recombinant human growth hormone (rhGH) reduced VAT and buffalo hump but presented significant adverse effects.
  • Metformin and thiazolidinediones improved metabolic parameters but did not correct body composition changes.
  • Anabolic steroids and l-carnitine demonstrated no efficacy in treating lipodystrophy.

Conclusions:

  • Currently, no pharmacologic agent fully corrects the cosmetic changes of HIV-associated lipodystrophy.
  • Treatment decisions require careful consideration of individual patient benefits and risks.
  • Personalized therapeutic strategies are essential for managing this condition.

Related Experiment Videos